Catherine Borg

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Liam G. Heaney, John Busby, Catherine E. Hanratty et al. · The Lancet Respiratory Medicine · 2020 · 137 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors.

Irina Knezevic, Catherine Borg, Guy C. Le Breton · Journal of Biological Chemistry · 1993 · 123 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

P. Jane McDowell, Sarah Diver, Freda Yang et al. · The Lancet Respiratory Medicine · 2021 · 110 citations

Life Sciences, Immunology, Pharmacotherapy +15

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma

Bart Hilvering, Timothy Hinks, Linda Stöger et al. · Mucosal Immunology · 2018 · 59 citations · Full text

Life Sciences, Immunology, Pathology +17

Purification of rat brain, rabbit aorta, and human platelet thromboxane A2/prostaglandin H2 receptors by immunoaffinity chromatography employing anti-peptide and anti-receptor antibodies.

Catherine Borg, C.T. Lim, David C. Yeomans et al. · Journal of Biological Chemistry · 1994 · 56 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15